Garden Bio-Chemical subsidiary wins national drug procurement bid for osteoporosis drug

Zhejiang Garden Bio-Chemical High-tech Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd., has successfully had its Alendronate Sodium Tablets selected in the eleventh batch of national centralized drug procurement. The announcement follows results published by the National Organization for Centralized Drug Procurement Office.

The selected product, Alendronate Sodium Tablets (70mg, 4 tablets/box), is indicated primarily for the treatment of postmenopausal osteoporosis in women and osteoporosis in men to increase bone mass. The procurement period for this product extends until December 31, 2028, with supply regions including Inner Mongolia, Jiangsu, Henan, Hunan, and Gansu.

This successful bid is expected to significantly benefit Zhejiang Garden Pharmaceutical by rapidly expanding its market reach and increasing market share for Alendronate Sodium Tablets. Furthermore, it is anticipated to boost the company's pharmaceutical preparation business, enrich its product pipeline, and enhance its brand influence. However, the company also issued a risk warning, advising investors to carefully consider investment risks as subsequent matters and the future impact on performance remain uncertain.